Is yervoy chemotherapy?

What is Yervoy and how does it work?

Yervoy, also known as ipilimumab, is a monoclonal antibody medication used to treat various types of cancer, including melanoma, renal cell carcinoma, and lung cancer [1]. It works by enhancing the body's immune system to recognize and attack cancer cells.

Is Yervoy chemotherapy?

No, Yervoy is not a traditional chemotherapy medication. While it is used to treat cancer, it is considered an immunotherapy, which uses the body's own immune system to fight cancer [2]. Unlike chemotherapy, which kills cancer cells directly, Yervoy works by blocking a protein called CTLA-4, which normally helps to regulate the immune response.

How does Yervoy compare to traditional chemotherapy?

Yervoy is often used as a single agent or in combination with other immunotherapies, such as nivolumab. In contrast, traditional chemotherapy typically involves a combination of medications that kill cancer cells directly. While chemotherapy can be effective, it often has more severe side effects than Yervoy.

Who makes Yervoy and when does its patent expire?

Yervoy is manufactured by Bristol-Myers Squibb (BMS) and was approved by the FDA in 2011. The patent for Yervoy initially expired in 2022, but BMS has been granted several extensions, including a patent for the injection form that expires in 2034 [3].

Can biosimilars enter the market before the patent expires?

Biosimilars are biologic medications that are similar to a reference product, such as Yervoy. However, the regulatory pathway for biosimilars can be complex, and it is unclear when or if biosimilars will be approved for Yervoy.

Sources:

[1] Yervoy (ipilimumab) - FDA
[2] Immunotherapy for Cancer Treatment - National Cancer Institute
[3] DrugPatentWatch.com - Ipilimumab Patent Expiration Date